UroGen Operating Income from 2010 to 2025
| URGN Stock | USD 11.40 0.50 4.20% |
Operating Income | First Reported 2014-12-31 | Previous Quarter -17.5 M | Current Value -27.7 M | Quarterly Volatility 11.2 M |
Check UroGen Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among UroGen Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 994.3 K, Interest Expense of 13.1 M or Selling General Administrative of 127.2 M, as well as many indicators such as Price To Sales Ratio of 4.8, Dividend Yield of 0.0 or Days Sales Outstanding of 97.34. UroGen financial statements analysis is a perfect complement when working with UroGen Pharma Valuation or Volatility modules.
UroGen | Operating Income |
Latest UroGen Pharma's Operating Income Growth Pattern
Below is the plot of the Operating Income of UroGen Pharma over the last few years. Operating Income is the amount of profit realized from UroGen Pharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of UroGen Pharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. UroGen Pharma's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in UroGen Pharma's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
UroGen Operating Income Regression Statistics
| Arithmetic Mean | (49,279,869) | |
| Coefficient Of Variation | (94.67) | |
| Mean Deviation | 43,093,994 | |
| Median | (19,950,000) | |
| Standard Deviation | 46,652,661 | |
| Sample Variance | 2176.5T | |
| Range | 127.5M | |
| R-Value | (0.82) | |
| Mean Square Error | 753.5T | |
| R-Squared | 0.68 | |
| Significance | 0.000091 | |
| Slope | (8,061,862) | |
| Total Sum of Squares | 32647.1T |
UroGen Operating Income History
Other Fundumenentals of UroGen Pharma
UroGen Pharma Operating Income component correlations
Click cells to compare fundamentals
About UroGen Pharma Financial Statements
UroGen Pharma investors utilize fundamental indicators, such as Operating Income, to predict how UroGen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | -96.8 M | -91.9 M | |
| Non Operating Income Net Other | 1.2 M | 672.1 K |
Check out the analysis of UroGen Pharma Correlation against competitors. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth 0.044 | Return On Assets | Return On Equity |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.